Perrigo Seeks FDA Approval For the First OTC Contraceptive Pill
Perrigo Company plc's (NYSE: PRGO) HRA Pharma has
ViaCyte Acquisition Can Accelerate Vertex’s Ongoing Type 1 Diabetes Programs
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has agreed to acquire ViaCyte, a privately held biotechnology, for $320 million in cash. ViaCyte is focused…
Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase…
FDA Signs Off Nyxoah’s Genio Trial In Complete Concentric Collapse Patients
The FDA has approved Nyxoah SA’s (NASDAQ:NYXH) Investigational Device Exemption (IDE) to initiate a trial, called ACCCESS, to evaluate the Genio…
Co-Diagnostics Announces Shipment Of Monkeypox Virus Test
Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that
Why Are Pliant Therapeutics Shares Rallying Today?
Pliant Therapeutics Inc’s (NASDAQ:PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and…
Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal
Innoviva Inc (NASDAQ:INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $5.95 per share, representing a premium of approximately 70%…
Arcutis Biotherapeutics Announces Health Canada Accepts For Review New Drug Submission For Roflumilast Cream For Adults And Adolescents With Plaque Psoriasis
Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studies
If approved, roflumilast cream would be the first and
T2 Biosystems Receives FDA Breakthrough Device Designation For T2Lyme Panel
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device
FDA Clears LPCN 2101 IND For Adult Epilepsy Treatment
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders with high unmet medical needs, announced